Metraipolis › archive › dc_799884bf78fe
Targeting PLK1 potentiates the antitumor efficacy of EGFR-TKIs through inhibiting the JAK1/STAT3 pathway — Europe PMC PMID:41539998
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41539998
- DOI
- 10.1038/s41419-[numero omesso]-9
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T19:12:13.482Z
- SHA-256 of the archived text
19b7069750db35bd0319c0aae3786e4ae1e3d47b21e8b1c5dc46d77a634cfca4- Stable URL of this page
https://metraipolis.com/documento/dc_799884bf78fe
How to cite
Targeting PLK1 potentiates the antitumor efficacy of EGFR-TKIs through inhibiting the JAK1/STAT3 pathway — Europe PMC PMID:41539998 — Europe PMC (en), https://europepmc.org/article/MED/41539998 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_799884bf78fe (Metraipolis archive dc_799884bf78fe, sha256 19b7069750db35bd0319c0aae3786e4ae1e3d47b21e8b1c5dc46d77a634cfca4)
BibTeX
@misc{dc799884bf78fe,
title = {Targeting PLK1 potentiates the antitumor efficacy of EGFR-TKIs through inhibiting the JAK1/STAT3 pathway — Europe PMC PMID:41539998},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41539998},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_799884bf78fe; sha256 19b7069750db35bd0319c0aae3786e4ae1e3d47b21e8b1c5dc46d77a634cfca4},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41539998. Agents can read the archived copy with the MCP tool read_document.